Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy Benefit

Inactivating mutations in the exonuclease domain of POLE induce somatic hypermutation resulting in a high tumor mutation burden (TMB) and are associated with immune checkpoint inhibitor (ICI) benefit. POLE mutations outside the exonuclease domain predicted to be deleterious are also observed in canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Sharlene, Zakaria, Heba, Hsiehchen, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Precision Medicine Clinic: Molecular Tumor Board
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914489/
https://www.ncbi.nlm.nih.gov/pubmed/35274726
http://dx.doi.org/10.1093/oncolo/oyac017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914489/
https://www.ncbi.nlm.nih.gov/pubmed/35274726
http://dx.doi.org/10.1093/oncolo/oyac017

Ejemplares similares